The Institute for Clinical and Economic Review (ICER) announced plans to assess FibroGen’s roxadustat for the treatment of anemia in chronic kidney disease.
An open input period will remain open until 5 p.m. EST July 15.
According to a press release, a document outlining the planned review will be posted July 20.
To read the full press release, click here.
